Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A comparison was made of the relief of pain after operation, obtained following the i.v. administration of buprenophrine and pethidine in 60 patients with lower abdominal incisions. No difference could be detected between the maximum analgesia produced by eigher drug, but analgesia following buprenorphine appeared to last about four times as long as that following pethidine. When the drugs were compared on a "dose per body weight" basis the results supported a ratio of potency in the order of 1 : 200 in favour of buprenorphine. Vomiting, drowsiness and dizziness were less frequent following buprenorphine, but a similar frequency of nausea was observed with both agents. Marked miosis occurred 5--10 min after the i.v. injection of buprenorphine, but no serious side-effects were observed with either drug. The i.v. injection of buprenorphine, but no serious side-effects were observed with either drug. The i.v. administration of buprenorphine appeared to be effective in the management of pain after operation in patients with lower abdominal incisions.
 ...
PMID:A comparison of buprenorphine and pethidine for immediate postoperative pain relief by the i.v. route. 66 36

Fifty fit, female patients were given four consecutive intravenous doses of etomidate 10 mg, so as to maintain sleep, after establishment of epidural block for postpartum sterilization. A matched group was given four doses of thiopentone 125 mg. Cumulative hypnotic effect, as judged by increasing sleep duration with second and subsequent doses, was much less with etomidate than with thiopentone. Etomidate did not depress blood pressure, whereas it fell progressively with successive doses of thiopentone. Injection pain was reported in 68% of patients receiving etomidate, and this tended to increase with successive doses; 12% also showed local inflammation at the injection site. Tremor, due to etomidate, was common, but did not increase with successive doses. Feelings of sleepiness, lasting several hours after waking, were more common after thiopentone than after etomidate.
 ...
PMID:Effects of etomidate given in repeated doses. 73 55

Butorphanol, 1, 2, and 4 mg/70 kg, and meperidine, 40 and 80 mg/70 kg, were compared for analgesic activity and side effects in 104 hospitalized postoperative patients. Butorphanol proved to be 30 to 40 times as potent as meperidine on a weight basis. Both medications provided maximum pain relief approximately 1 hr after administration. The most common side effect in all groups was drowsiness.
 ...
PMID:Intramuscular butorphanol and meperidine in postoperative pain. 78 74

The relief of acute migraine attacks with an analgesic/antihistamine combination containing paracetamol, codeine phosphate, doxylamine succinate and caffeine (Mersyndol) compared with that achieved with a placebo has been studied in a double-blind, crossover trial. Mersyndol emerged as significantly better than placebo in the complete relief of migraine pain, and was clearly superior to placebo in partially relieving the pain of migraine. These results suggest that it could be a useful alternative to ergotamine, and a comparative trial with ergotamine is suggested. Side effects with this combination were fairly common but mild, and consisted mainly of drowsiness caused by the antihistamine component.
 ...
PMID:Treatment of migraine attacks with an analgesic combination (Mersyndol). 78 38

A double-blind, randomized trial was conducted with 124 post-operative patients to compare the analgesic activity and possible side-effects of a new synthetic analgesic--butorphanol tartrate (1, 2, and 4 mg)--and pentazocine lactate (30 and 60 mg), adminstered intramuscularly. Butorphanol was determined to be 16 times more potent than pentazocine, on a weight basis. Both medications provided maximum pain relief within one hour after administration, and had comparable durations of action. Drowsiness was the most common side-effect, and it appeared to be dose related in all test groups.
 ...
PMID:Butorphanol: a double-blind comparison with pentazocine in post-operative patients with moderate to severe pain. 79 96

A double-blind clinical study of analgesic drugs was conducted involving 47 healthy adults requiring removal of 90 bony impacted mandibular third molars. The analgesic effect of paracetamol plus codeine (P + C) 350 + 20 mg was compared to that of acetylsalicylic acid (ASA) 500 mg and placebo. A standardized surgical procedure under local anesthesia was used. Insufficient analgesic effect was noted in 16% of the ASA group and in 69% of the placebo group but in none in the P+C group. On the first postoperative day, patients given P+C suffered less pain compared with those given ASA (P less than 0.01). No relationship could be demonstrated between the type of impaction and intensity of pain. Trismus, however, was found to be associated with difficulty of extirpation. Drowsiness and an increased sleeping tendency were the main side effects found in the P+C group. The incidence of secondary hemorrhage was high in the ASA group, compared with the P+C group a significance of 0.01 less than P less than 0.05 was found on various postoperative days. Registration of swelling revealed less postoperative edema in the P+C group than in the ASA group (0.01less thanPless than0.05). The main conclusion from this study is that the analgesic effect of P+C orally administered after a specific oral surgical procedure is superior to ASA and placebo. P+C also appears to have a more marked antiphologistic effect than ASA.
 ...
PMID:Paracetamol/codeine in relieving pain following removal of impacted mandibular third molars. 81 88

In a series of 84 various evaluable disseminated cancer patients treated with hydrazine sulfate as a result of a pharmaceutical-sponsored investigational new drug (IND) study, it was found that 59/84 or 70% of the cases improved subjectively and 14/84 or 17% improved objectively. Subjective responses included increased appetite with either weight gain or cessation of weight loss, increase in strength and improved performance status and decrease in pain. Objective responses included measurable tumor regression, disappearance of or decrease in neoplastic-associated disorders and long-term (over 1 year) 'stabilized condition'. Of the overall 59 subjective improvements 25 (42%) had no concurrent or prior (within 3 months) anticancer therapy of any type. Of the 14 objective improvements 7 (50%) had no concurrent or prior anticancer therapy. Of the remaining cases in which there was either concurrent or prior anticancer therapy, improvements occurred only after the addition of hydrazine sulfate to the treatment regimen. Duration of improvement was variable, from temporary to long-term and continuing. Side effects were mild, comprising for the most part low incidences of extremity paresthesias, nausea, pruritus and drowsiness; there was no indication of bone marrow depression.
 ...
PMID:Use of hydrazine sulfate in terminal and preterminal cancer patients: results of investigational new drug (IND) study in 84 evaluable patients. 120 24

Phase I of a clinical study of Ukrain was performed in 19 healthy outpatient volunteers. Their general clinical conditions were evaluated, as well as the following parameters: biochemical, haematological, immunological, electrolyte and trace elements, neopterin, immune complexes and non specific blocking factors. Ukrain was administered intramuscularly (i.m.) or intravenously (i.v.) every one, two or three days in doses of 5 to 50 mg for 7 to 40 days. In one case the drug was administered for three years in the dose of 5 to 50 mg/injection in repeated courses. During the investigation no significant changes were found in clinical states. During the intramuscular injections the volunteers felt only localized pain; some reported drowsiness, increased thirst and polyurea. There was a slight, insignificant increase in body temperature and negligible decrease of blood pressure in some cases. In conclusion, it can be said that Ukrain is well tolerated in healthy volunteers in the doses of 5, 10, 20, and 50 mg/injection, even during prolonged (up to three years) administration.
 ...
PMID:Clinical studies of Ukrain in healthy volunteers (phase 1). 130 42

Sleep physiology, viral serology and symptoms of 14 patients with chronic fatigue syndrome (CFS) were compared with 12 healthy controls. All patients described unrefreshing sleep and showed a prominent alpha electroencephalographic nonrapid eye movement (7.5-11.0 Hz) sleep anomaly (p less than or equal to 0.001), but had no physiologic daytime sleepiness. There were no group differences in Epstein-Barr virus (EBV) antibody titers. The patient group had more fibrositis tender points (p less than 0.0001), described more somatic complaints (p less than 0.0001), and more depressive symptoms (p less than 0.0001). Patients with CFS do not show evidence for a specific chronic EBV infection, but show altered sleep physiology, numerous tender points, diffuse pain, and depressive symptoms. These features are similar to those found in fibromyalgia syndrome.
 ...
PMID:Sleep, Epstein-Barr virus infection, musculoskeletal pain, and depressive symptoms in chronic fatigue syndrome. 132 33

Fifty-one patients with moderate (11/51) and severe (40/51) cancer pain were given a new non-narcotic analgesic -Tromadol HCL capsule (THC). In 42 of these patients, partial relief was obtained with an average relief time (ART) of 4.1 hours. The average starting time was 58 minutes. Pain relief rate (PRR) in moderate and severe pain was 82% (P = 0.945), and the ARTs were 7.4 hr. and 3.2 hr., respectively (P = 0.005). In 43 patients who were entered into a randomized study with control drugs of AT-237 (36 cases) or Anfendein (7 cases), the PRR was 60.4% (26/43), ART was 1.3 hours. The PRR and ART of THC and control drugs were statistically significant (P less than 0.001 and P = 0.023). Within adequate dose range, increase of THC dose could improve its analgesic effect (P = 0.011). The main side-effects were: somnolence (37.3%), nausea (35.3%), dizziness (33.3%), palpitation and anorexia (25.5%) and constipation (9.8%) which did not necessitate the suspension of THC administration.
 ...
PMID:[Pain-relief effect of tramadol HCL capsule for moderate and severe cancer pain]. 139 64


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>